XML 44 R37.htm IDEA: XBRL DOCUMENT v3.25.3
Revenue - Additional Information (Details) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended
May 31, 2023
Feb. 28, 2019
Sep. 30, 2025
Sep. 30, 2024
Jun. 30, 2023
Sep. 30, 2025
Sep. 30, 2024
Disaggregation Of Revenue [Line Items]              
Revenue from collaboration agreement     $ 93,973,000 $ 46,435,000   $ 205,295,000 $ 131,498,000
Immune Medicine Service Revenue              
Disaggregation Of Revenue [Line Items]              
Revenue from collaboration agreement     33,700,000 3,500,000   41,300,000 10,000,000
Medicare Reimbursements              
Disaggregation Of Revenue [Line Items]              
Revenue from collaboration agreement       1,500,000   7,300,000 4,300,000
Medicare Reimbursements | Immune Medicine Service Revenue              
Disaggregation Of Revenue [Line Items]              
Revenue from collaboration agreement     2,900,000        
MRD Development Agreements | Maximum              
Disaggregation Of Revenue [Line Items]              
Additional milestone payment receivable     384,000,000     384,000,000  
Genentech Collaboration Agreement              
Disaggregation Of Revenue [Line Items]              
Revenue from collaboration agreement         $ 7,700,000    
Non-refundable upfront payments received   $ 300,000,000       300,000,000  
Additional transaction price of regulatory milestone payment $ 10,000,000            
Expected revenue through milestone payments     1,800,000,000     1,800,000,000  
Genentech Collaboration Agreement | Regulatory Milestones              
Disaggregation Of Revenue [Line Items]              
Additional transaction price of regulatory milestone payment $ 10,000,000            
Genentech Collaboration Agreement | Maximum | Regulatory Milestones              
Disaggregation Of Revenue [Line Items]              
Expected revenue through milestone payments     65,000,000     65,000,000  
Genentech Collaboration Agreement | Maximum | Development Milestones              
Disaggregation Of Revenue [Line Items]              
Expected revenue through milestone payments     300,000,000     300,000,000  
Genentech Collaboration Agreement | Maximum | Commercial Milestones              
Disaggregation Of Revenue [Line Items]              
Expected revenue through milestone payments     $ 1,430,000,000     $ 1,430,000,000  
Cancelled Customer Contracts              
Disaggregation Of Revenue [Line Items]              
Revenue from collaboration agreement             $ 1,100,000
Cancelled Customer Contracts | Immune Medicine Service Revenue              
Disaggregation Of Revenue [Line Items]              
Revenue from collaboration agreement       $ 1,000,000